PMC10200986_01
MRI scans on admission. (A, B) Brain MRI (axial fluid-attenuated inversion recovery image) exhibiting the area postrema lesion (red arrows, including one in Figure C). (C, D) Spinal cord MRI (sagittal T2-weighted image) showing demyelinating lesions in the cervical and thoracic segments (white arrows).
fimmu-14-1164181-g001.jpg
PMC10200986_01_fimmu-14-1164181-g001.jpg
f1
Brain MRI suggested the area postrema lesion and spinal cord MRI showed demyelinating lesions in the cervical and thoracic segments ( Figure 1 ).
Schematic illustration of the disease course showing relapse frequency and core symptoms, disability severity, treatment regimens and CD19+ B-cell monitoring.
fimmu-14-1164181-g002.jpg
PMC10200986_01_fimmu-14-1164181-g002.jpg
f2
As of 19 April 2023, she had received twelve subcutaneous injections of OFA with no relapse, a CD19+ B-cell percentage of 0, and a serum IgM level of 17.0 mg/dL ( Figure 2 ).